Podda A, Carapella De Luca E, Titone L, Casadei A M, Cascio A, Bartalini M, Volpini G, Peppoloni S, Marsili I, Nencioni L
Biocine-Sclavo R&D Vaccines, Siena, Italy.
J Pediatr. 1993 Jul;123(1):81-4. doi: 10.1016/s0022-3476(05)81543-4.
We studied the immunogenicity of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin (PT-9K/129G), filamentous haemagglutinin, and a 69-kilodalton protein, pertactin, in 30 children aged 12 to 24 months and in 80 infants aged 2 to 4 months. A significant increase of the neutralizing titer and of the titers against pertussis toxin, filamentous hemagglutinin, and pertactin, as determined by enzyme-linked immunosorbent assay, was achieved after three doses of vaccine in all the children; a significant increase of these antibody titers was obtained in 100%, 96.1%, 93.5%, and 98.7% of the infants, respectively.
我们在30名12至24个月大的儿童以及80名2至4个月大的婴儿中研究了一种无细胞百日咳疫苗的免疫原性，该疫苗由基因解毒的百日咳毒素（PT-9K/129G）、丝状血凝素和一种69千道尔顿的蛋白质——百日咳黏附素组成。通过酶联免疫吸附测定法测定，所有儿童在接种三剂疫苗后，中和效价以及针对百日咳毒素、丝状血凝素和百日咳黏附素的效价均显著提高；在婴儿中，这些抗体效价分别在100%、96.1%、93.5%和98.7%的婴儿中显著提高。
